HCMR Re-Imaging for Hypertrophic Cardiomyopathy Follow-up

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational follow-up enrolls participants from the original HCMR cohort to repeat cardiac MRI with gadolinium and compare imaging findings to clinical outcomes. The study focuses on measuring late gadolinium enhancement (LGE) and other MRI markers of fibrosis and structure, then tracking arrhythmias, heart failure events, and related complications. No experimental treatments are given; investigators will collect imaging and clinical data and analyze associations between imaging features and subsequent risk. The goal is to refine which imaging signs best predict adverse events in people with HCM.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients in the original HCMR cohort with:

1. Obstructive HCM

   * Males and females between 18 and 65 years of age
   * BMI \< 35 kg/m2
   * LVOT-G at entry as follows:

   Resting gradient ≥50 mmHg OR Resting gradient ≥30 mmHg and \<50 mmHg with post-Valsalva LVOT-G ≥50 mmHg

   • NYHA Class II or III or
2. Non-obstructive HCM

   * Same criteria as above except resting LVOT-G is \<30mmHg and post-Valsalva gradient \<50mm Hg
   * BMI \<40kg/m2
   * Elevated NT-proBNP \> 300 pg/mL at the time of enrollment
   * LVEF ≥55%

Exclusion Criteria:

* Paroxysmal atrial fibrillation or flutter documented prior to entry.
* Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to entry. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for \>6 months.)
* History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to entry.
* Pregnancy due to potential risk of gadolinium to the fetus
* Patients with a pacemaker that are pacer-dependent as they cannot undergo MRI

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting
• University of Virginia
  Charlottesville, Virginia, United States Recruiting
• Barts Health NHS Trust
  London, United Kingdom Recruiting
• Brigham & Women's Hospital
  Boston, Massachusetts, United States Not yet recruiting
• Tufts Medical Center
  Medford, Massachusetts, United States Not yet recruiting
• University of Michigan
  Ann Arbor, Michigan, United States Not yet recruiting

Study contacts

• Principal investigator: Christopher Kramer, MD — University of Virginia
• Study coordinator: Gina Duda
• Email: gms4x@uvahealth.org
• Phone: 434-924-9553

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Transitioning from mavacamten to aficamten in obstructive HCM

  This study tests whether switching from mavacamten to aficamten is feasible and safe for people with obstructive hypertrophic cardiomyopathy who are already on mavacamten.

  Recruiting Phase 4 Oregon Health and Science University · Kansas City, Missouri and 1 other locations · NCT07600177

• 68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases

  This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07464132

• Understanding why AF happens and is harder to treat in hypertrophic cardiomyopathy

  We’re testing how heart electrical signals and advanced imaging relate to atrial fibrillation in people with hypertrophic cardiomyopathy to see if treatments can be improved.

  Recruiting Guy's and St Thomas' NHS Foundation Trust · London · NCT07454135

• UK multicentre hypertrophic cardiomyopathy registry

  This project collects health information from adults with hypertrophic cardiomyopathy across UK NHS hospitals to see which treatments and tests work best for different patients.

  Recruiting University of Manchester · Manchester · NCT07381894

• Multimodal analysis of heart biopsy samples

  This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT07359690

• T1 mapping to characterize heart tissue in common heart diseases

  This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing, Beijing Municipality · NCT07354646

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.